VIR250117C17500
- 0.10
- -0.06-37.50%
Vir Biotechnology Newsroom
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Express News | Vir Biotechnology Inc : Morgan Stanley Raises to Overweight From Equal-Weight
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Upgrades Vir Biotechnology(VIR.US) to Buy Rating, Raises Target Price to $20
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $110
Vir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic Partnerships
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Sana Biotechnology SANA Cell Therapy Data; Vir Biotechnology VIR Phase 1 Data
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Vir Biotech Upgraded at Morgan Stanley on Cancer Drug Data
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $14 to $28
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Analyst Ratings
Morgan Stanley Upgrades Vir Biotechnology to Overweight From Equalweight, Adjusts Price Target to $20 From $10
Vir Biotechnology (VIR) Gets a Buy From Barclays
Express News | Vir Biotechnology Inc : JP Morgan Raises Target Price to $14 From $10
Vir Biotechnology's Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties